Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Program)
Source: View publication →
In patients with type 2 diabetes and high cardiovascular risk, canagliflozin significantly reduced the risk of major adverse cardiovascular events and heart failure hospitalizations, but was associated with an increased risk of lower extremity amputations.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CANVAS program cemented SGLT2 inhibitors as a foundational, disease-modifying therapy for patients with type 2 diabetes and elevated cardiovascular risk, providing robust evidence for MACE and heart failure reduction. However, the unexpected discovery of increased lower extremity amputations significantly altered clinical practice, necessitating thorough diabetic foot exams and cautious prescribing in patients with severe peripheral artery disease or a history of prior amputations.
Historical Context
Following the 2008 FDA mandate requiring cardiovascular outcome trials (CVOTs) for new diabetes medications, EMPA-REG OUTCOME (2015) was the first to show cardiovascular mortality benefits for an SGLT2 inhibitor (empagliflozin). Published in 2017, the CANVAS program demonstrated that these broad benefits (MACE reduction, heart failure protection, and renal preservation) extended to canagliflozin, strongly supporting a drug class effect. The unexpected amputation risk led to a temporary FDA boxed warning for canagliflozin, which was later removed in 2020 after further real-world data and subsequent trials provided a clearer, more favorable safety profile.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of canagliflozin, an SGLT2 inhibitor, explain both its cardiovascular benefits, such as reduced heart failure hospitalizations, and its common adverse effects, like genitourinary infections?
Key Response
Canagliflozin blocks sodium and glucose reabsorption in the proximal convoluted tubule. This induces glycosuria, which causes an osmotic diuresis that lowers preload and blood pressure (benefiting heart failure), but the increased glucose concentration in the urinary tract creates an optimal environment for mycotic genitourinary infections.
Given the CANVAS trial demonstrated both cardiovascular benefits and a twofold increased risk of lower-extremity amputations, how should this influence your patient selection, physical exam, and counseling for a diabetic patient with comorbid peripheral artery disease?
Key Response
Residents must weigh efficacy against safety. For a patient with peripheral artery disease, neuropathy, or prior foot ulcers, the amputation signal in CANVAS necessitates a careful baseline foot exam, intensive counseling on preventive foot care, and potentially selecting an alternative agent with proven CV benefit (like empagliflozin or a GLP-1 RA) that did not demonstrate a prominent amputation risk in its landmark trial.
The CANVAS program showed potential renoprotective effects alongside its cardiovascular benefits. Hemodynamically, how does SGLT2 inhibition alter tubuloglomerular feedback to achieve these long-term renal benefits, and how does this explain the characteristic transient 'dip' in eGFR upon initiation?
Key Response
SGLT2 inhibition increases distal sodium delivery to the macula densa, which restores tubuloglomerular feedback and triggers adenosine-mediated afferent arteriolar vasoconstriction. This reduces intraglomerular hypertension and hyperfiltration, leading to an initial, reversible decrease in eGFR that ultimately preserves long-term nephron function.
The unexpected lower-extremity amputation risk in CANVAS sparked immense debate over whether it was a canagliflozin-specific effect or an SGLT2 inhibitor class effect. How does this finding shape your approach to evaluating new, isolated safety signals in large cardiovascular outcome trials, and how do you teach your team to contextualize this risk clinically?
Key Response
Attendings must navigate ambiguity in evidence. Because EMPA-REG and DECLARE-TIMI did not show this amputation signal to the same degree, it raised questions about molecule specificity versus trial population/surveillance differences. Teaching focuses on not hastily discarding a life-saving medication class, but rather individualizing therapy, increasing vigilance, and critically assessing subsequent real-world pharmacovigilance data.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CANVAS Program uniquely integrated data from two separate trials (CANVAS and CANVAS-R) to maximize statistical power for cardiovascular outcomes. What are the methodological implications and potential threats to validity of pooling data from trials with overlapping but distinct designs, particularly regarding alpha-spending and hierarchical testing sequences?
Key Response
CANVAS was unblinded early for a regulatory interim analysis, and CANVAS-R was later added to accrue enough events. Pooling these creates challenges in maintaining statistical rigor, requiring complex hierarchical testing to control the family-wise error rate across multiple endpoints while ensuring that the early unblinding did not introduce operational bias into the remainder of the program.
Interim data from the original CANVAS trial were unblinded early to regulatory authorities to assess cardiovascular safety. As a reviewer, how would you evaluate the potential introduction of operational bias due to this early data release, and what statistical or structural firewalls would you demand to see before accepting the validity of the final composite MACE endpoint?
Key Response
Early unblinding is a major red flag for reviewers. If investigators, sponsors, or trial steering committees alter trial conduct, recruitment, or endpoint adjudication based on interim results, it fundamentally threatens the trial's integrity. Reviewers must rigorously scrutinize the data access protocols, blinding maintenance, and statistical penalties applied for interim analyses to ensure the type I error was not inflated.
Following the CANVAS program, how should guidelines balance a strong Class I recommendation for SGLT2 inhibitors in patients with T2DM and established ASCVD against the trial's specific safety signal of amputations, and should guidelines differentiate between specific agents within the SGLT2i class based on this data?
Key Response
Guideline committees (e.g., ADA, ACC/AHA) must synthesize conflicting safety signals across a class. While the CV and heart failure benefits warrant high-level recommendations, the amputation signal led to temporary FDA Boxed Warnings. Guidelines addressed this by issuing class-level recommendations for ASCVD/HF benefit, but added specific caveats advising comprehensive foot exams and caution when using canagliflozin in patients at high risk for amputation, reflecting a nuanced, patient-centered application of the evidence.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME
Tested
Empagliflozin 10mg or 25mg daily
Population
T2DM patients with established cardiovascular disease
Comparator
Placebo
Endpoint
3-point MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke)
DECLARE-TIMI 58
Tested
Dapagliflozin 10mg daily
Population
T2DM patients with or at risk for atherosclerotic cardiovascular disease
Comparator
Placebo
Endpoint
Composite of 3-point MACE and composite of cardiovascular death or hospitalization for heart failure
CREDENCE
Tested
Canagliflozin 100mg daily
Population
T2DM patients with chronic kidney disease and albuminuria
Comparator
Placebo
Endpoint
Composite of end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis